Patient case activities

Once an accurate diagnosis has been achieved, the most appropriate and tailored treatment plan needs to be developed.

In the competence phase, a series of four case studies will help you understand the most appropriate acute treatment based on both the severity of the patient’s migraine and any contraindications or complications they may have. They will also look at the emerging therapies that could further optimize the acute treatment of migraine.

Learn more about patients with migraine and co-morbidities and how to adapt their treatment plan accordingly, addressing the complication of medication overuse.
Publishing date: 12th May 2021

Learn more about classifying patients who present with refractory migraine attacks and which emerging therapeutics can best help manage their symptoms.
Publishing date: 4th March 2021

Learn more about classifying patients who present with moderate-to-severe attacks and which emerging therapeutics can best help manage their symptoms.
Publishing date: 27th Februay 2021

Learn more about classifying patients who present with mild-to-moderate attacks and which emerging therapeutics can best help manage their symptoms.
Publishing date: 28th January 2021

eLearning activity

To ensure optimal management of migraine, patients need to be regularly monitored and their treatment reviewed.

In this eLearning module you will be shown how to measure treatment success, utilizing patient-reported outcome (PRO) tools, to ensure a patient’s treatment is amended when required and patient satisfaction is improved.

Uwe Reuter discusses how to assess the efficacy of migraine treatment and when to change treatment plans.

Would you like to know more?

Register for a free account and you'll be the first to know when new content is available
Scroll to Top

Mario Peres

Professor, Psychiatry Institute, Sao Paulo University, Sao Paulo, Brazil

Mario Peres is a neurologist, who for the past 20 years has been dedicated to headache research, clinical practice, academic training and public awareness. He is currently President of ABRACES, a Brazilian headache advocacy association, Secretary of the Brazilian Headache Society, member of the Board of Trustees of the International Headache Society, and Professor at the Psychiatry Institute, University of Sao Paulo, Brazil.


Mario Peres discloses financial support/sponsorship from Lilly, Allergan, and Novartis in speaker fees, and consultation fees from Eurofarma, Lilly, Sanofi. Peres holds patent # BR2020170233532, from INPI – Instituto Nacional da Propriedade Industrial. Registered on 30/10/2017.

Nada Hindiyeh

Nada Hindiyeh is a board certified Neurologist and headache specialist and is currently a Clinical Assistant Professor in the department of Neurology at Stanford University. She is the Director of Clinical Research for the Stanford division of Headache Medicine and serves as principal investigator for several clinical trials.

Dr Hindiyeh was awarded the 2013 Clinical Research Fellowship in Neurotoxins by the American Academy of Neurology and under this scholarship is currently investigating a diagnostic screening protocol for chronic migraine. Other research interests include pathophysiology and novel treatments for migraine, the use of transcranial magnetic stimulation in headache disorders, and participation in clinical trials for new headache therapeutics. She is currently a member of the American Headache Society (AHS), serves on the AHS Electronic Media committee and was chosen as an AHS Emerging Leader in the field in 2017. She is also a member of the International Headache Society.

Dr Hindiyeh completed her medical degree at the University of Toledo College of Medicine in Toledo Ohio. Both her internship and neurology residency were completed at the University of California, Irvine, Medical Center, where she was chief resident. She completed her fellowship in headache and facial pain at Stanford University School of Medicine.


Nada Hindiyeh has received consultation fees from Eli Lilly and Lundbed

Uwe Reuter, Program Director

Professor of Neurology, Charité University Hospital, Berlin, Germany

Prof Dr Uwe Reuter is a neurologist and partner in the headache program at Charité Universitätsmedizin Berlin, Germany. Upon completing his residency training in Berlin he attended Harvard Medical School as a postdoctoral fellow. During his time in Boston he focused on basic research in primary headaches and migraine aura, and published several peer-reviewed publications in high impact journals. Uwe Reuter has been the principal investigator in numerous clinical trials and projects. He has published multiple manuscripts on CGRP and is the lead author in the first placebo controlled clinical trial with a monoclonal CGRP antibody for migraine prevention in patients, who previously did not respond to 2-4 conventional oral migraine preventatives.

He is a member of several national and international headache organizations and currently serves as a board member of the European Headache Federation.


Uwe Reuter discloses financial support and/or sponsorship from Allergan, Amgen, Novartis, Eli Lilly, TEVA, Medscape, and StreamedUp.

Shih-Pin Chen

Attending Neurologist and Professor, Department of Medical Research and Department of Neurology, Taipei Veterans General Hospital, Taipei, TAIWAN

Shih-Pin Chen is a physician and scientist who graduated from Faculty of Medicine and Institute of Clinical Medicine, National Yang-Ming University, Taiwan. He received his neurology resident training at Department of Neurology, Taipei Veterans General Hospital and post-doctoral fellowship training at Neurovascular Research Lab, Massachusetts General Hospital, Harvard Medical School, USA.

Dr Chen is currently an attending physician of Department of Medical Research, Taipei Veterans General Hospital and Professor of Institute of Clinical Medicine, National Yang-Ming University. He has served as the Associate Editor of Cephalalgia (the official journal of the International Headache Society) and Cephalalgia Reports since 2020. Dr Chen’s research interests focus on deciphering the pathophysiology of headache disorders, specifically, the clinical, neuroimaging, and molecular biological studies of reversible cerebral vasoconstriction syndrome (RCVS) as well as the animal models (especially cortical spreading depression) and genomics studies of migraine.


Shih-Pin Chen discloses speaker honorarium from Eli Lilly & Company.

Sign up for eAlerts or take our quiz first and sign up at the end.